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mia during follow-up between 5 months and 4 years. The other 60 
patients remained negative in GBV-C PCR.
One important route of GBV-C transmission is blood products (blood 
plasma and erythrocyte and thrombocyte concentrates).4 Therefore, we 
examined the number of blood products administered to these patients 
in connection with liver transplantation. We did not find a significant 
difference between the number of blood products administered to the 
42 patients who acquired GBV-C infection perioperatively (median, 142 
U) and the 60 patients without GBV-C infection (median, 137.5 U).
From our results we conclude that GBV-C infection is not linked 
to fulminant hepatitis. Our data further show that patients who un­
dergo liver transplantation are at high risk for acquiring GBV-C 
infection. The prevalence after transplantation was 41.2%, in contrast 
to 6.4% before transplantation. Transfusion-transmitted GBV-C in­
fection has to be assumed due to the great number (median, 140 U) 
required for liver transplantation. This is in agreement with pre­
viously published data in patients with hematologic malignancy.5 
Clinical studies are already in progress to evaluate the clinical impact 
of GBV-C infection in liver transplant recipients.
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MLL Cleavage Occurs in Approximately 5% of De Novo Acute Myeloid Leukemia, Including in Patients 
Analyzed Before Treatment Induction
To the Editor:
Apian et a l1 recently reported a site-specific DNA cleavage in­
duced by topoisomerase 11 (Topo II) inhibitors within the MLL 
gene breakpoint cluster region on chromosome 1 lq23. The finding 
was initially identified by Southern blot analysis o f circulating 
blasts taken from a case of T-cell acute lymphoblastic leukemia 
(T-ALL) 16 hours after the induction of multiagent chemotherapy, 
including doxorubicin, a known inhibitor of Topo II. The investiga­
tors subsequently reproduced the same pattern of DNA fragmenta­
tion by in vitro culture of malignant cell lines with doxorubicin 
and etoposide, showing that cleavage was not restricted to the T- 
lymphoid lineage because it was observed in B-lymphoid, myeloid, 
and nonhematopoietic malignant cell lines and even in the periph­
eral blood lymphocytes of normal individuals. They suggested that 
Topo II inhibitor induced MLL cleavage correlated with sensitivity 
to epidophyllotoxins and that lymphoid lines may be more sensitive 
to such cleavage, because it was observed in 4 of 6 malignant T-
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Fig 1. Southern blot analysis 
of BamHI-, EcoRI-, and Bgl Indi­
gested DNA from patients no. 
593 and 975, compared with a 
placenta negative control (NC). 
The sizes (in kilobases) of the 
germline bands are indicated by 
arrows and the rearranged 
bands as lines. The 2 faint 4^- 
and ^4,3-kb bands in the BamHi 
digest from patient no. 593 are 
probably due to star activity, be­
cause they are not seen in other 
digests.
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Table 1. Clinical (A) and Molecular (B) Characteristics of AML Patients With MLL Cleavage
A. Patient Characteristics
Patien t No. Age/Sex FAB WBC % Age Blasts
593
722
975
35/M
38/M
55/M
M5
M4
M4
104
160
23.5
96
80
42
B. Southern Blot Hybridization With the B859 cDNA and 19 Genomic Probes
Restriction Enzyme GermJine Fragments (kb)
Bam HI 
HindiW 
Bgl III 
EcoR\
8.3 
15
3.1, 6
4.6, 5, 4
Cytogenetics
46,XY [25]
46,XY[1]/47,XY, 4-8 [39] 
46,XY [20]
Fragments Induced by 
Topo II inhibitor (kb)*
6,7, 1.5
12.5,2^5 
3.1, 4.6, 1,4 
4.6, 5, (ÓJ), 3.3
* The 3 fragment identified by the 19 genomic probe is underlined. The 0.7-kb fragment in EcoRI digests is unlikely to be detected with a 
cDNA probe in view of its size and limited exon content.
cell lines and 3 of 4 B-cell lines, but in only 1 of 6 myeloid cell 
lines and 1 of 6 solid tumor cell lines. We show here that an 
identical MLL DNA cleavage occurs relatively frequently in de 
novo AML and that it is not restricted to cases analyzed after 
induction with Topo II inhibitors.
Having demonstrated that MLL rearrangements occur frequently 
in de novo acute myeloid leukemia (AML) of diverse French- 
American-British (FAB) subtypes,2 we have instituted routine 
screening for MLL rearrangement for patients included in the 
EORTC/GIMEMA AML 10 trial (No. 06931) by Southern blot 
hybridization of BamHl and ///«dill-digested DNA with an MLL 
cDNA probe, B859, encompassing exons 5 through l l 3 (kindly 
provided by Guiseppe Cimino, La Sapienza, Rome, Italy). Briefly, 
this trial includes patients 15 to 60 years of age with untreated, 
newly diagnosed AML of all FAB subtypes other than M3. Seventy 
clinical centers from 9 countries submit patients to AML 10, but 
the current molecular analysis is restricted to data from the French 
centers, which represent approximately 10% of patients. Parallel 
molecular analyses are performed on Dutch, Belgian, and Italian 
patients. Patient recruitment for the French centers started in Janu­
ary 1994 and prospective molecular screening began in January 
1996. All patients with cryopreserved material obtained between 
January 1994 and January 1996 were studied retrospectively. MLL 
status was assessed by Southern blotting in 62 of 96 (65%) patients 
from the French centers included in the AML 10 protocol between 
January 1994 and April 1996. Whereas 9 of 62 (15%) of patients 
were shown to have major MLL rearrangements, a further 3 (5%) 
patients showed minor, bialielic rearranged bands with both en­
zymes, with identically sized BamHl fragments to those identified 
by Apian et al.1 The intensity of the rearranged bands corresponded 
to approximately 5% to 10% of the DNA (Fig 1). Further analysis 
of EcoRl and Bgl II digested DNA (Fig 1) from 2 of these 3 cases 
with the B859 cDNA and an intron 9 genomic probe, 19,2 showed 
that the MLL breakpoint localized to the 2-kb EcoRl-Bgl II geno-
genomic 19 probe. BamHl analysis of patient no. 593 showed 2 
further minor rearrangements of approximately 4.3 and 4 kb (Fig 
1), which are compatible with a second cleavage site, but these 
bands were not detected with other digests and may therefore repre­
sent star activity. The possible presence of a minor translocation 
leading to transcription of one of the common AML fusion tran­
scripts was analyzed in patient no. 593, but RT-PCR analysis failed 
to show MLL-AF6, MLL-AF9, MLL-ENL, MLL-ELL, or MLL 
duplication (data not shown).
In contrast to the T-ALL reported by Apian et al,1 samples from 
all 3 patients were taken before the induction of chemotherapy. 
Clinical and biologic details of the patients are shown in Table 1. 
All 3 were men and presented with monocytic M4/5 AML, in 
which karyotypic llq23 abnormalities are found most frequently.4 
Questioning did not show any prior malignancy or chemotherapy 
and there was no apparent exposure to toxic agents. Cytogenetic 
analysis was normal in 2 patients and the third demonstrated an 
isolated trisomy 8. The only finding of possible relevance was the 
presentation white blood cell (WBC) count, because both patients 
with easily detectable MLL cleavage had marked leukocytosis 
at diagnosis. The original case described by Apian et a l1 also 
showed a high presentation blast count, as is commonly found in 
T-ALL.
We therefore show that 5% of patients with AML demonstrate 
MLL cleavage in a minor proportion of blasts tested before the 
induction of chemotherapy. This observation has obvious signifi­
cance for the interpretation of Southern blots in routine molecular 
diagnostic screening, when it is conceivable that a proportion of 
apparent MLL rearrangements may in fact be MLL cleavage. It is 
also interesting with regard to the known capacity of Topo II inhibi­
tors to induce secondary leukemias with MLL rearrangement, as 
discussed by Apian et al.1 It would obviously be interesting to 
determine whether MLL cleavage is more common in relapsed 
AML. Our data also suggest that MLL cleavage may occur prefer-
mic fragment containing exons 9 and 10 of the breakpoint cluster entially in cases with a rapid cell doubling time. This intrinsic
region, with the size of the rearranged fragments identified (Table 
1) corresponding exactly to the breakpoint putatively localized to 
a Topo II consensus recognition sequence 1,470 bp 5' of the BamHl 
site at the 3' extremity of the breakpoint cluster region.1 Both 
rearranged bands were of equivalent intensity in patients no. 593
propensity may be further accentuated by treatment with Topo II 
inhibitors. Routine molecular screening of AML at diagnosis, as 
undertaken in the EORTC/GIMEMA AML 10 trial, will allow us 
to determine whether MLL cleavage has prognostic significance, 
particularly with regard to secondary malignancies, provided that
and 722 («10% ; Fig 1 and data not shown), whereas the 5' frag- this particular Southern blot profile is recognized, 
ment was relatively weak in Bgl II digests from patient no. 975,
with the 3' fragment more clearly visible when probed with B859 
(Fig 1). The amount of cleaved DNA was lower in this patient 
and no clear rearranged band could be discerned with the 300-bp
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Consensus Conference on Unrelated Donor Bone Marrow Transplantation: Royal College of Physicians of 
Edinburgh, October 29th and 30th, 1996
To the Editor: CONSENSUS CONFERENCE ON UNRELATED
DONOR BMT
The role of unrelated donor bone marrow transplantation (BMT) 
in the treatment of leukemia has been an area of controversy for 
some years. Although there has never been any doubt that occasional 
patients are cured by this procedure, sometimes at advanced stages 
of their disease, the place of such transplants in the routine manage­
ment o f children and adults with leukemia has not been defined 
clearly. To address the current problems in this area and to identify, 
if possible, areas o f future development, a Consensus Conference 
was organized. This conference brought together experts in the man­
agement of leukemia, using both conventional and transplantation 
techniques in adults and children, health economics, and medical 
ethics. New concepts such as the use of umbilical cord blood cells 
and immunotherapy were also addressed.
A panel, under the chairmanship of Prof E.C. Gordon-Smith (St 
George’s Hospital, London, UK) was convened to hear the presenta­
tions and to prepare a consensus statement. The panel members 
(see below) included an expert in BMT, a general hematologist, a 
pediatrician, patient advocates, and a medical journalist. The panel 
was asked to consider, if possible, four questions about unrelated 
donor BMT. These were to identify the current indications for such 
transplants in adults and children, to consider what was appropriate 
in terms of donor care, and to consider what studies might contribute 
to improved evaluation of the procedure. In addition to the presenta­
tions given at the conference, the panel also had received in advance 
the four background papers published subsequently in Blood Re­
views. These papers were sent to referees for comment and were 
amended in the light of these comments before being distributed to 
the panel members.
During the 2-day conference, the Consensus Panel produced the 
Consensus Statement, which follows. In addition to making recom­
mendations about how published reports on unrelated donor BMT 
should present results, the statement makes strong recommendations 
with regard to the introduction of molecular typing at both HLA 
class I and II to ensure optimal matching between donor and recipient 
and, in addition, proposes that current differences be removed be­
tween the management of family and unrelated donors with regard 
to the use of hemopoietic growth factor mobilized peripheral blood 
stem cells (PBSC).
OCTOBER 29-30, 1996
Its Use in Leukemias and Allied Disorders
BMTs from unrelated donors for leukemias are increasing greatly 
in number and also in proportion to matched sibling donor trans­
plants. The panel has considered unrelated donor transplant (UD- 
BMT) on the basis of efficacy, toxicity, and indications in leukemias. 
The conclusions and statements are based largely but not exclusively 
on information provided at the Consensus Conference.
(1) Unrelated BMTs for some types of leukemia can produce 
prolonged quiescence and, in some cases, eradication of disease.
(2) Data based on serologically matched donors at HLA A,B and 
DR suggest that matched unrelated transplants may have similar 
survival to sibling transplants in comparable disease states. This is 
accepted as a reasonable statement but begs the question of what 
is implied by matched in unrelated transplants. Much of the data 
concerning the survival and toxicity in unrelated transplants have 
come from studies using serologic typing. The effect of molecular 
typing on outcome may alter indications.
(3) Information on the place of sibling transplants compared with 
chemotherapy and autologous transplants in the management of 
some leukemias has been provided by randomized studies organized 
by the EORTC and the MRC. These studies define the place of 
sibling BMT in the management of acute leukemias. Conclusions 
drawn from these studies on the presence or absence of benefit of 
sibling transplants may apply to unrelated transplants.
(4) In a few situations, the evidence for efficacy is based on the 
level 1 documentation of zero survival after conventional therapy 
but with some survivors after transplant (eg, childhood acute lym­
phoblastic leukemia [ALL] with early bone marrow relapse). How­
ever, in situations in which alternative therapies occasionally suc­
ceed, level 1 evidence from randomized trials is rarely available to 
help in decision making.
(5) There is variation in outcome reported from different sources 
for particular conditions. In part, this may be because subdivisions 
of different types of leukemia are not always accurately defined.
